心不全における内皮機能障害の対処:内皮原細胞の役割と新しい治療の見通し

Eugenio Carulli^1,2, Marialuisa Sveva Marozzi^3,4, Maria Cristina Carella^1,5

¹Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari Bari, Italy.

Cardiac failure review

|September 3, 2025

まとめ

心不全は内皮機能障害で血管の修復に影響します内皮原細胞 (EPC) を標的とし,内皮の健康を改善する治療法により,心不全の改善が期待されています.

科学分野:

心血管研究
血管生物学
再生医療

背景:

心不全 (HF) は内皮機能障害と有意に関連しています.
HFの内皮機能不全は,窒素酸化物の減少,酸化ストレス,炎症,血管機能の低下を伴う.
機能不全の内皮原生細胞 (EPC) は,HFの進行と結果を悪化させる.

研究の目的:

心不全における内皮機能障害の新興治療法を検討する.
血管修復とHFにおける内皮原細胞 (EPC) の役割を強調する.
内皮のメカニズムを標的とした新しい治療法の治療の可能性を議論する.

主な方法:

内皮機能障害と心不全の最近の進歩に関する文献レビュー.
抗酸化剤,遺伝子療法,細胞ベースのアプローチを含む治療戦略の分析.
ステチンやSGLT2阻害剤のような薬理学的薬剤の内皮効果の評価

主要な成果:

特にEPCの動員と機能を強化する新興療法が有望である.
抗酸化物質,遺伝子,EPCベースの戦略は,HFにおける血管修復の可能性を提供します.
ステチンとSGLT2阻害剤は,内皮の健康とEPCの活性を改善し,プレオトロピー効果を発揮する.

結論:

内皮機能障害とEPCを標的とした治療は心不全の有望な治療法です
HF患者の治療結果を改善するために,内皮を標的とする治療法を最適化するために,さらなる研究が不可欠です.
心臓不全を効果的に管理するには血管の健康に関する包括的な戦略が不可欠です

キーワード:

内皮機能障害内皮原細胞心不全窒素酸化物新しい治療戦略酸化ストレス血管再生

さらに関連する動画

07:26

Isolation of Endothelial Progenitor Cells from Human Umbilical Cord Blood

Published on: September 14, 2017

11.3K

13:46

Phenotypic and Functional Characterization of Endothelial Colony Forming Cells Derived from Human Umbilical Cord Blood

Published on: April 13, 2012

16.4K

関連する概念動画

01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

505

01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

01:17

Pathophysiology of Heart Failure

1.8K

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...

1.8K

01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.